Adaptimmune Therapeutics (ADAP)

Executive Summary

Adaptimmune Therapeutics, a UK-based clinical-stage biopharmaceutical company, has undergone a significant strategic pivot in 2025, divesting its lead clinical assets to focus on its core TCR-T cell therapy platform. The company now operates as a leaner entity with a streamlined team, listed on the OTC Pink market, and holds a current valuation of approximately $14.5 million. Its sole active pipeline asset is ADP-TILIL7, an engineered T-cell product targeting stage III/IV melanoma, currently in a Phase 1 trial (NCT06204991) initiated in April 2025, with estimated completion in 2028. While the company’s technology holds promise for solid tumors, the early-stage nature of its pipeline, limited financial resources, and low public market visibility pose substantial risks. Adaptimmune’s future hinges on successful clinical execution, potential partnerships, or alternative financing to advance its programs.

Upcoming Catalysts (preview)

• H2 2026Initial safety and efficacy data from Phase 1 ADP-TILIL7 trial in melanoma30% success
• TBDPotential partnership or licensing deal for ADP-TILIL7 or platform technology20% success
• Q3 2026Announcement of strategic alternative such as reverse merger or financing25% success